ROCKVILLE, Md., Oct. 2, 2018 /PRNewswire/ -- REGENXBIO Inc. RGNX, a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced that it will present at the Chardan 2^nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 4:15 p.m. ET at the Westin Grand Central, New York.

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors

Natalie Wildenradt, 646-681-8192

natalie@argotpartners.com

Media

Adam Pawluk, 202-591-4063

apawluk@jpa.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-2nd-annual-genetic-medicines-conference-300723170.html

SOURCE REGENXBIO Inc.